Do feasibility studies contribute to, or avoid, waste in research?

PLoS ONE

Volumn 13, Issue 4, 2018, Pages

  Morgan, Ben ^a   Hejdenberg, Jennie ^a   Hinrichs Krapels, Saba ^b   Armstrong, David ^b  

^a The National Institute for Health Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London in partnership with UK Health Security Agency   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CLINICAL TRIAL (TOPIC); FEASIBILITY STUDY; FUNDING; HUMAN; INVESTMENT; PUBLISHING; QUESTIONNAIRE; COST BENEFIT ANALYSIS; ECONOMICS; METHODOLOGY; PROCEDURES; TIME FACTOR;

CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; FEASIBILITY STUDIES; HUMANS; RESEARCH DESIGN; TIME FACTORS;

EID: 85045898090     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0195951     Document Type: Article

References (12)

1. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. Lancet 2009; 374: 86–89. https://doi.org/10.1016/S0140-6736(09)60329-9 PMID: 19525005
2. Chalmers I, Bracken MB, Djulbegovic B, Garattini S, Grant J, Gülmezoglu AM, et al. How to increase value and reduce waste when research priorities are set. Lancet 2014; 383: 156–165. https://doi.org/10.1016/S0140-6736(13)62229-1 PMID: 24411644
3. Stensland KD, McBride RB, Latif A, Wisnivesky J, Hendricks R, Roper N, et al. Adult cancer clinical trials that fail to complete: An epidemic? JNCI J Natl Cancer Inst 2014; 106(9): dju229 https://doi.org/10.1093/jnci/dju229 PMID: 25190726
4. Eldridge SM, Lancaster GA, Campbell MJ, Thabane L, Hopewell S, Coleman CL, et al. Defining feasibility and pilot studies in preparation for randomised controlled trials: development of a conceptual framework. PLoS ONE 2016; 11(3): e0150205. https://doi.org/10.1371/journal.pone.0150205 PMID: 26978655
5. Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials BMJ 2016; 355:i5239 https://doi.org/10.1136/bmj.i5239 PMID: 27777223
6. Riveros C, Dechartres A, Perrodeau E, Haneef R, Boutron I, Ravaud P. Timing and completeness of trial results posted at ClinicalTrials.gov and published in journals. PLoS Med 2013; 10(12): e1001566. https://doi.org/10.1371/journal.pmed.1001566 PMID: 24311990
7. Hwang TJ, Carpenter D, Lauffenburger JC, Wang B, Franklin JM, Kesselheim AS. Failure of investiga-tional drugs in late-stage clinical development and publication of trial results. JAMA Intern Med. 2016; 176(12):1826–1833. https://doi.org/10.1001/jamainternmed.2016.6008 PMID: 27723879
8. Miller JE, Korn D, Ross JS. Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012. BMJ Open 2015; 5: e009758. https://doi.org/10.1136/bmjopen-2015-009758 PMID: 26563214
9. Chen R, Desai NR, Ross JS, Zhang W, Chau KH, Wayda B,et al. Publication and reporting of clinical trial results: cross sectional analysis across academic medical centers. BMJ 2016; 352:i637 https://doi.org/10.1136/bmj.i637 PMID: 26888209
10. Schmucker C, Schell LK, Portalupi S, Oeller P, Cabrera L, Cabrera L, et al. Extent of non-publication in cohorts of studies approved by research ethics committees or included in trial registries. PLoS ONE 2014; 9(12): e114023. https://doi.org/10.1371/journal.pone.0114023 PMID: 25536072
11. Song F, Parekh S, Hooper L, Loke YK, Ryder J, Sutton AJ,et al. Dissemination and publication of research findings: an updated review of related biases. Health Technology Assessment 2010; 14: No. 8 https://doi.org/10.3310/hta14080 PMID: 20181324
12. Chinnery F, Young A, Goodman J, Ashton-Key M, Milne R. Time to publication for NIHR HTA programme-funded research: a cohort study. BMJ Open 2013; 3: e004121. https://doi.org/10.1136/ bmjopen-2013-004121 PMID: 24285634